|1.||Wilson, W R: 2 articles (12/2000 - 02/2000)|
|2.||Prous, J R: 1 article (06/2005)|
|3.||Bayés, M: 1 article (06/2005)|
|4.||Rabasseda, X: 1 article (06/2005)|
|5.||Son, Yung H: 1 article (01/2005)|
|6.||Sartorelli, Alan C: 1 article (01/2005)|
|7.||Rockwell, Sara: 1 article (01/2005)|
|8.||Fischer, James J: 1 article (01/2005)|
|9.||Haffty, Bruce G: 1 article (01/2005)|
|10.||Ross, Douglas A: 1 article (01/2005)|
08/01/2000 - "Porfiromycin (PM), a bioreductive alkylating agent, is currently under development for the treatment of head and neck cancers as an adjunct to radiation therapy in phase III clinical trials. "
05/01/1993 - "The studies reported here examine the effects of porfiromycin (POR), a bioreductive alkylating agent shown previously to be preferentially toxic to hypoxic EMT6 cells in vitro and in solid tumors in young adult mice. "
01/01/1975 - "Phase I studies of porfiromycin (NSC--56410) in solid tumors."
01/01/1995 - "Preferential kill of hypoxic EMT6 mammary tumor cells by the bioreductive alkylating agent porfiromycin."
07/01/1991 - "[3H]-(N-la-methyl) Porfiromycin (POR) was employed to detect and identify the radiolabeled mono- and bis-adducts formed in living EMT6 mouse mammary tumor cells under different conditions. "
12/01/2000 - "Tirapazamine is the second clinical anticancer drug (after porfiromycin) that functions primarily as a hypoxia-selective cytotoxin. "
08/31/1999 - "Expression of the bacterial mcrA gene in mammalian Chinese hamster ovary cells causes profound resistance to mitomycin C and to its structurally related analog porfiromycin under aerobic conditions but produces little change in drug sensitivity under hypoxia. "
04/10/1998 - "Transfectants expressing the cytosolic enzyme were restored to parental line sensitivity to both mitomycin C and porfiromycin in air with marked increases in drug sensitivity under hypoxia. "
01/01/1991 - "The agents examined included mitomycin C, porfiromycin, and the 7-aminomethyl dithioacetal derivative of mitomycin C (BMY-43324), all of which caused greater kill of hypoxic cells than of their oxygenated counterparts; the N,N'-dimethylaminomethylene derivative of mitomycin C (BMY-25282), which was considerably more cytotoxic under oxygenated conditions than in hypoxia; and the N,N'-dimethylaminomethylene derivative of porfiromycin (BL-6783), which was equal in its toxicity to hypoxic and oxygenated cells. "
04/10/1998 - "Although this enzyme activates the mitomycins in vitro, its overexpression in living cells caused decreases in sensitivity to mitomycin C in air and decreases in sensitivity to porfiromycin under both air and hypoxia. "
09/15/1989 - "The mechanism of uptake and efflux of porfiromycin (PFM) by HCT 116 human colon carcinoma cells or freshly obtained human RBC was investigated. "
09/15/1989 - "Mechanism of transport and intracellular binding of porfiromycin in HCT 116 human colon carcinoma cells."
06/01/1991 - "Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo."
01/01/1985 - "Using primarily the EMT6 mouse mammary carcinoma as a solid tumor model, we have found that mitomycin C and porfiromycin are preferentially toxic to cells with low oxygen contents. "
01/01/1990 - "The cytotoxicity, metabolism, and DNA alkylation of porfiromycin (PFM) under aerobic and hypoxic conditions were evaluated in P388 murine leukemia cells. "
03/01/1969 - "The effect of treatment with a combination of 6-mercaptopurine and porfiromycin on an established Friend leukemia virus infection."
|5.||Squamous Cell Neoplasms (Squamous Cell Cancer)
|2.||NAD(P)H Dehydrogenase (Quinone) (Quinone Reductase)
|4.||DNA (Deoxyribonucleic Acid)
|9.||apaziquone (E 09)